What are Personalized Medical Solutions? Personalized Medicines (PM) in the Pharmaceutical Industry is a system and strategy that is adapted to provide a curated and personalized treatment where the prescription of medications for a person is offered as per their medical requirements and needs. This system and strategy is also known as Precision Medicine. Under the Diagnostic Department, the analysis of Genetics, Biomarkers, and Lifestyles of people are taken into account and personalized medications are curated for patients.
Personalized Medicine is a recent system that is being adopted and it takes into regard the patient’s Genetic Profile. Using the information obtained from patients, doctors, and professional medical experts would then be able to make the appropriate decisions and take the appropriate steps to properly diagnose, treat, prevent, and prescribe medications. This strategy can be used to obtain a proper diagnosis of patients with the same disease but with other differences concerning their family history, lifestyle, genetics, and biomarkers.
This is where Pharmaceutical Compounding and Sterile Outsourcing Services come into play in pharmaceutical innovations. Pharmaceutical Compounding is the process or the series of steps involved where a particular number of two or more drug ingredients are taken and combined, mixed, and altered in their composition, doze, or quantity, to create a compound that is personalized and curated according to the patient’s requirements and needs. Pharmaceutical Compounding can be categorized into Sterile Compounding (medication that is injected into the system) and Non-Sterile Compounding (medication that is used orally and topically).
Sterile Outsourcing Services in hospital pharmacies and outpatient surgery facilities require Section 503B as per the Federal, Food, Drug, and Cosmetics Industry (FDA) and the Drug Enforcement Administration (DEA), to provide and offer the supply of sterile products and equipment to improve and increase patient safety and quality assurances when providing healthcare to patients in the hospitals. Therefore, with the use of Pharmaceutical Compounding and Sterile Outsourcing Services in the pharmaceutical industries, companies can use this strategy to become facilitators of creating and providing medications that are personalized and specifically curated for patients.
Another reason for this approach is to combat the lack of continuing certain medications over time and discontinuing specific medications that help a certain demographic. Hence, in this article, we will be looking into the journey of one such pharmaceutical company that specializes in Pharmaceutical Compounding and Sterile Outsourcing Services.
Fagron – Brands and Essentials, US with Rafael Padilla:
Fagron – Brands and Essentials, US – was founded in the year 1990 by Ger van Jeveren, in Rotterdam, Netherlands. With its headquarters situated there, this company was established and has been in active business ever since. The current CEO of Fagron is Rafael Padilla who took on the role of leading the pharmaceutical solutions company from 2017. With the experiences obtained over the years from working in many managerial positions within the organization, Rafael Padilla has managed to apply his skills and talent to ensure that business operations are successfully established in Southern Europe and in Latin America as well.
About Fagron:
Fagron is one such company that personalizes medicines by pharmaceutical compounding and provides sterile outsourcing services to pharmacists, hospitals, medical industries, and prescribers so that a range of personalized medicines and equipment can be provided to also maintain safety and quality assurances in overall healthcare. This strategy helps in curbing expenses making it cost-effecting to purchase regularly as well as to increase its efficacies in treating patients.
Ensuring that the specifically curated and personalized medications created by pharmaceutical compounding are accessible by people of all demographics, geographics, and ages so that the medicines that they need and require can be easily accessed and afforded.
With the motto of ESG – Environmental, Social, and Governance embedded deeply into the roots and foundations of the business and company, Fagron has successfully managed to be responsible in their works and deeds for over 34 years now. Protecting and conserving biodiversity and the earth’s environment has always been a priority for Fagron.
“We aim to globally deliver, ready-to-use and ready-to-administer innovative and high-quality personalized solutions that enhance medical compliance and significantly improve healthcare.” – Fagron’s Aim.
This is one of the reasons why the company has massively branched out to over 30+ countries, namely – Europe, the Middle East, Africa, North America, and Latin America. Additionally, its sterile and non-sterile facilities that supply medications and equipment to pharmacies, hospitals, etcetera, are situated in the Netherlands, Belgium, the Czech Republic, Israel, the United States of America, Columbia, and South Africa.
Having over 4,000+ suppliers that provide the needed drugs and ingredients to Fagron, the attributes that help in determining a great supply vendor are – hygiene, quality assurance, and compliance, fair and responsible business practices, competitive, responsive, sustainable, creative, innovative, and reliable in the long-term. With around 70+ on-site facilities around the world, 406 actively working pharmacists, over 1,000+ Active Pharmaceutical Ingredients (APIs), over 375 branded products and equipment, and around 2,000 working medical experts and professionals in the industry, almost 300,000 patients’ needs are met by Fagron.
To Conclude: Fagron is a global leader in the creation and supply of personalized medications that are specifically curated to meet patients’ individual needs, in the pharmaceutical manufacturing of Fagron products. With pharmaceutical compounding and sterile outsourcing services, the business has since been working for over 34 years in over 35+ countries and has grown massively in operations with the guidance and leadership of CEO – Rafael Padilla. This pharmaceutical solution and strategy were adopted to provide the patients whose medications have either been commercially discontinued, temporarily stopped by the government, and are inaccessible and unaffordable.